

**Announcement  
30 April 2012****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2012 Coloplast has launched a share buy-back programme for up to DKK 1bn. The first part of the programme, of DKK 500m, is expected to take place during the period from 1 February 2012 to 30 September 2012. The second stage of the programme is expected to take place from 1 October, 2012 to 30 September, 2013.

Under the first of the programme the following transactions have been executed during the period 23 – 27 April 2012:

<b>Date</b>	<b>Number of shares</b>	<b>Average buying price</b>	<b>Amount DKK</b>
23.4.2012	11,183	972.85	10,879,382
24.4.2012	6,999	970.01	6,789,100
25.4.2012	4,200	969.67	4,072,614
26.4.2012	1,000	968.00	968,000
27.4.2012	5,500	1,034.00	5,687,000
<b>Accumulated until now under the programme</b>	256,501	933.13	239,349,895

Henceforth, Coloplast owns 2,876,068 own B shares of DKK 5 equal to 6.39% of the company's total share capital.

Share buy-back in the amount of DKK 260,650,105 remains under the first part of the programme.

## **For further information, please contact**

### **Investors and analysts**

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1700

Ian S.E. Christensen  
Vice President, Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

Henrik Nord  
Investor Relations Manager  
Tel. +45 4911 1800/+45 4911 3108  
Email: dkhno@coloplast.com

### **Press and the media**

Ulla Lundhus  
Media Relations Manager  
Tel. +45 4911 1929  
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2012-4 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 7,500 people.